We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vernalis | LSE:VER | London | Ordinary Share | GB00B3Y5L754 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.17 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/1/2017 14:11 | Vernalis plc (LSE: VER) announces that its unaudited interim results for the six months ended 31 December 2016 will be released on Tuesday, 21 February 2017. | bountyhunter | |
25/1/2017 13:16 | Just a ten bagger will do! | fhmktg | |
25/1/2017 10:01 | 'On such things dreams are made' | fhmktg | |
25/1/2017 09:34 | chrisdgb I need an avalanche to get me to the British biotech price | barrie16 | |
25/1/2017 08:29 | Drift........no interest?! | chrisdgb | |
05/1/2017 13:23 | Better volume here today, would be nice for this stock to break out of its trading range..! | chrisdgb | |
29/12/2016 15:51 | Anyone know what's happening? Not seen any news to justify todays surge. | bantam175 | |
21/12/2016 23:46 | Thanks Hastings! | fhmktg | |
21/12/2016 21:24 | Thanks, FHMKTG. Really down to marketing then (and hopefully a particularly busy cough and cold season to give them an initial boost and brand recognition. imo | cumnor | |
21/12/2016 17:25 | Cumnor, the active ingredients are all approved and Tris formulations are know to the FDA so approval should be reasonably assured! | fhmktg | |
21/12/2016 14:00 | any idea on cash n debt levels. holding from before consolidation. need £6.61 to break even | latifs100 | |
21/12/2016 13:43 | "six unique extended-release equivalents to existing immediate-release prescription cough cold treatments" there's a huge potential market here - if they can get all or most of these through the FDA then imo this could multibag many times over! | bountyhunter | |
21/12/2016 09:45 | Anyone know if 'full review' means they are likely to be passed? | cumnor | |
21/12/2016 09:31 | Three medications on the market for season 17/18 if all goes to schedule. | fhmktg | |
21/12/2016 08:38 | Stifel raise price target today to 104p............. | chrisdgb | |
20/12/2016 14:20 | Well, let us hope the Tuzistra prescriptions are moving nicely higher...... | chrisdgb | |
16/12/2016 13:35 | Somebody stakebuilding?250k bought today. | fhmktg | |
01/12/2016 15:20 | Ah well! Never mind! | fhmktg | |
01/12/2016 13:50 | Some good buying packets going through; be interesting if it continues when New York opens! | fhmktg | |
01/12/2016 11:43 | VER need to identify an FDA registered company with experience of antibiotic production and get them approved and registration quantities made hence the 24 month timescale. | fhmktg | |
01/12/2016 09:53 | Yes, and we do need something to turn the share price direction around. Re: "The project to identify a replacement source of supply for Moxatag(R) is progressing to plan." ...it's good to hear that there is a plan but what is it! ...we could do with a little more information on this to improve investor confidence. | bountyhunter | |
01/12/2016 09:37 | Nice bit of optimism in today's agm statement. Start of a long slog back to growth.Three more years before the full family of medicines are in place and a takeover emerges? | fhmktg | |
23/11/2016 19:35 | Hmm-suspicious dumping in progress? Time to buy or are mgmt holding bad news back, enabling some a cushy exit before letting the masses in on it? 25P worth a punt, if they have any cash left? imo | cumnor | |
03/11/2016 16:38 | that is a very good question as surely they could have acquired it at a reduced price. | twodegrees |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions